Histogen IncOver The Counter Market:HSTOQ
- LAST PRICE0.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HSTOQ |
|---|---|---|
| 09:32 ET | 1500 | 0.02 |
| 11:38 ET | 10416 | 0.02 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Histogen Inc | 85.4K | 0.0x | --- |
Hypertension Diagnostics Inc | 280.0 | --- | --- |
Oncologix Tech Inc | 166.3K | 0.0x | --- |
Harrison Vickers and Waterman Inc | 10.1K | 0.0x | --- |
Sunvault Energy Inc | 302.9K | -0.1x | --- |
Drazcanna Inc | 164.2K | 0.0x | --- |
Company Information
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Contact Information
- Headquarters
- 10655 SORRENTO VALLEY ROAD, SUITE 200SAN DIEGO, CA, United States 92121
- Phone
- 858-526-3100
- Fax
- 302-636-5454
Executives
- Non-Executive Chairman of the Board
- Daniel Kisner
- Chief Financial Officer, Chief Operating Officer, Executive Vice President, Corporate Secretary
- Susan Knudson
- Independent Director
- David Crean
- Independent Director
- Rochelle Fuhrmann
- Independent Director
- Jonathan Jackson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $85.4K |
|---|---|
Revenue (TTM) | $19.0K |
Shares Outstanding | 4.3M |
Histogen Inc does not pay a dividend. | |
Beta | 0.96 |
EPS | $-2.90 |
Book Value | $3.37 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -63,442.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
